Pharmaceutical

Novartis’ ribociclib approved in Canada for early breast cancer

Health Canada has granted a notice of compliance for Novartis Canada’s Kisqali (ribociclib tablets) plus an aromatase inhibitor.

Jun 21, 2025 - 06:00
Novartis’ ribociclib approved in Canada for early breast cancer
Health Canada has granted a notice of compliance for Novartis Canada’s Kisqali (ribociclib tablets) plus an aromatase inhibitor.
Read the original article

Tags:

Previous Article

Podcast: The benefits of blockchain in healthcare

Next Article

FDA cell and gene therapy director exit increases ‘volatility’ for sector

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Matt Eyles, CEO of America’s Health Insurance Plans, to depart

STAT+: Matt Eyles, CEO of America’s Health Insurance Pl...

May 25, 2023

Actio gains $66m to advance small molecule therapeutics pipeline

Actio gains $66m to advance small molecule therapeutics...

Jun 21, 2025

Suspected suicide attempts surged among youth during pandemic, study shows

Suspected suicide attempts surged among youth during pa...

Apr 21, 2023